MapLight Therapeutics (MPLT) Total Current Liabilities (2024 - 2026)
MapLight Therapeutics (MPLT) posted Total Current Liabilities of $16.2 million for Q4 2025, down 12.57% sequentially from $18.6 million in Q3 2025, and up 1.94% YoY from $15.9 million in Q4 2024.
MapLight Therapeutics (MPLT) Total Current Liabilities (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Total Current Liabilities for 2 years, with the latest figure at $16.2 million in Q4 2025.
- Quarterly Total Current Liabilities rose 1.94% year-over-year to $16.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.2 million (up 1.94% YoY) and the FY2025 annual result came in at $16.2 million, up 1.94% from the prior year.
- Total Current Liabilities eased to $16.2 million in Q4 2025 per MPLT's latest filing, from $18.6 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $18.6 million in Q3 2025 and troughed at $15.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - | 19.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.29 Mn |
| Dec 31, 2025 | 16.23 Mn |
| Sep 30, 2025 | 18.56 Mn |
| Dec 31, 2024 | 15.92 Mn |